AIM Stock Price, AIM ImmunoTech Inc Quote, Chart

Market Summary

USD0.41+0.02

Market Closed

5.13%

AIM Alerts

2 major insider buys recently.

AIM Stock Price

View Fullscreen

AIM RSI Chart

AIM Valuation

Market Cap

21.0M

Price/Earnings (Trailing)

-0.68

Price/Sales (Trailing)

108.94

Price/Free Cashflow

-0.94

AIM Price/Sales (Trailing)

AIM Profitability

Operating Margin

-708.29%

Return on Equity

-644.8%

Return on Assets

-192.22%

Free Cashflow Yield

-106.55%

AIM Fundamentals

AIM Revenue

Revenue (TTM)

193.0K

Rev. Growth (Yr)

-18.37%

Rev. Growth (Qtr)

-38.46%

AIM Earnings

Earnings (TTM)

-31.1M

Earnings Growth (Yr)

-58.89%

Earnings Growth (Qtr)

53.75%

Breaking Down AIM Revenue

Last 7 days

2.5%

Last 30 days

-14.6%

Last 90 days

7.9%

Trailing 12 Months

-18%

How does AIM drawdown profile look like?

AIM Financial Health

Current Ratio

1.14

Debt/Equity

0.2

Debt/Cashflow

-23.58

AIM Investor Care

Shares Dilution (1Y)

5.94%

Diluted EPS (TTM)

-0.64

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	193.0K	0	0	0
2023	156.5K	168.5K	193.5K	202.0K
2022	167.0K	146.0K	134.0K	140.5K
2021	190.0K	201.0K	198.0K	206.0K
2020	950.0K	961.0K	936.0K	163.0K
2019	0	832.0K	860.0K	1.6M
2018	409.0K	229.0K	177.0K	859.0K
2017	178.3K	264.5K	350.8K	437.0K
2016	122.8K	112.5K	102.3K	92.0K
2015	558.6K	345.8K	239.4K	133.0K
2014	765.8K	715.4K	690.2K	665.0K
2013	1.1M	0	970.0K	791.0K
2012	1.3M	0	0	1.3M
2011	669.3K	1.2M	1.7M	2.3M
2010	0	0	0	135.0K
2009	0	0	0	111.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of AIM ImmunoTech Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 06, 2024	equels thomas k	bought	25,000	0.405	61,729	ceo & president
May 06, 2024	rodino peter w iii	bought	12,500	0.405	30,865	coo, secretary, gen. counsel
Mar 21, 2024	bryan nancy	bought	15,000	0.39	38,462	-
Mar 15, 2024	appelrouth stewart	bought	30,000	0.33	90,910	-
Mar 15, 2024	rodino peter w iii	bought	12,500	0.33	37,879	coo, secretary, gen. counsel
Mar 15, 2024	equels thomas k	bought	25,000	0.33	75,758	ceo & president
Nov 27, 2023	equels thomas k	bought	15,000	0.443	33,861	ceo & president
Sep 29, 2023	equels thomas k	bought	10,000	0.441	22,676	ceo & president
Aug 25, 2023	equels thomas k	bought	5,500	0.669	8,222	ceo & president
Aug 24, 2023	equels thomas k	bought	10,000	0.667	14,993	ceo & president

Which funds bought or sold AIM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-9,351	-	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-14,965	-	-%
May 15, 2024	Royal Bank of Canada	added	0.56	-	-	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	3,387	51,292	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	10,089	10,089	-%
May 15, 2024	CAPTRUST FINANCIAL ADVISORS	unchanged	-	622	9,420	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-3.78	251	8,565	-%
May 15, 2024	Community Bank, N.A.	unchanged	-	529	6,216	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-98.31	-26.00	-	-%
May 15, 2024	MORGAN STANLEY	added	10.35	6,174	40,186	-%

Are Funds Buying or Selling AIM?

Are funds buying AIM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AIM

No. of Funds

AIM Alerts

2 major insider buys recently.

Unveiling AIM ImmunoTech Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 03, 2024	deutsch todd	3.5%	1,716,100	SC 13D/A
Aug 28, 2023	deutsch todd	3.5%	1,716,100	SC 13D/A
Aug 07, 2023	deutsch todd	3.5%	1,716,100	SC 13D/A
Jul 27, 2023	deutsch todd	3.5%	1,716,100	SC 13D
Feb 08, 2021	hudson bay capital management lp	0.02%	7,747	SC 13G/A
Feb 14, 2020	anson funds management lp	4.9%	434,030	SC 13G/A
Jan 31, 2020	hudson bay capital management lp	9.99%	917,198	SC 13G
Sep 30, 2019	anson funds management lp	9.9%	1,277,222	SC 13G

Recent SEC filings of AIM ImmunoTech Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 01, 2024	EFFECT	EFFECT
May 01, 2024	424B5	Prospectus Filed
Apr 19, 2024	S-1	Initial Public Offering
Apr 01, 2024	10-K	Annual Report
Mar 27, 2024	4	Insider Trading
Mar 27, 2024	4	Insider Trading
Mar 22, 2024	4	Insider Trading

Peers (Alternatives to AIM ImmunoTech Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

AIM ImmunoTech Inc News

Latest updates

AIM ImmunoTech Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Revenue	-38.5%	40.00	65.00	46.00	42.00	49.00	57.00	21.00	30.00	33.00	50.00	33.00	51.00	72.00	42.00	36.00	40.00	45.00	815	61.00	29.00	732
Costs and Expenses	-59.0%	5,774	14,069	8,203	5,503	4,344	5,612	6,542	4,725	3,185	7,496	3,962	3,741	3,773	5,183	3,391	3,380	3,370	3,138	3,266	3,253	2,901
S&GA Expenses	-100.0%	-	10,857	5,439	2,550	2,292	3,578	5,170	2,181	2,072	2,617	1,799	2,145	2,112	2,584	2,085	1,717	2,268	1,484	1,846	1,942	1,632
R&D Expenses	-39.0%	1,951	3,200	2,734	2,953	2,052	2,107	1,372	2,475	1,036	-	2,006	1,317	1,424	2,275	1,102	1,463	898	1,437	-	-	-
Interest Expenses	-	72.00	-	-	-	-	-	-	-	-	-	-1.00	19.00	50.00	53.00	51.00	249	322	-	-	-	-
Net Income	53.7%	-5,817	-12,576	-7,816	-4,909	-3,661	-4,389	-6,385	-4,851	-3,820	-5,746	-3,826	-5,913	-3,742	-3,965	-3,306	-3,303	-3,794	-527	-2,948	-2,036	-1,621
Net Income Margin	-12.5%	-161.23*	-143.38*	-107.36*	-114.80*	-123.23*	-138.40*	-155.24*	-124.95*	-115.60*	-93.33*	-88.11*	-84.21*	-75.35*	-88.15*	-	-	-	-	-	-	-
Free Cashflow	50.6%	-4,822	-9,765	-5,678	-2,165	-3,687	-6,076	-4,975	-2,320	-2,765	-5,752	-3,465	-1,727	-3,054	-2,863	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-16.5%	16,189	19,381	27,861	33,617	37,462	40,488	46,285	50,884	54,155	57,699	63,080	66,722	74,089	64,584	64,164	50,123	42,407	20,754	22,490	13,808	15,965
Current Assets	-22.3%	11,306	14,556	22,742	28,869	33,160	36,321	41,150	46,045	50,380	50,213	38,037	41,325	51,219	40,310	39,757	35,165	29,710	10,446	12,621	3,754	5,855
Cash Equivalents	-39.4%	3,295	5,439	15,264	21,038	23,395	27,053	29,759	34,452	28,989	32,093	37,349	41,142	48,773	38,501	38,496	33,908	27,590	1,470	9,616	959	2,394
Net PPE	-7.1%	118	127	136	145	155	195	118	127	137	4,047	5,994	6,145	6,311	6,473	6,629	6,785	6,950	7,116	7,292	7,465	7,602
Liabilities	24.2%	11,363	9,147	7,365	5,584	3,802	2,020	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current Liabilities	14.1%	9,876	8,652	4,716	2,885	1,837	1,361	2,895	1,368	766	673	767	876	970	1,102	795	833	703	1,127	4,191	1,747	2,087
Long Term Debt	-	950	-	-	-	-	-	-	-	-	-	-	-	1,816	1,876	1,934	1,993	2,050	2,104	2,158	2,213	2,267
LT Debt, Current	-	1,623	-	-	-	-	-	-	-	-	-	-	-	234	230	226	221	217	214	210	205	201
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	1,816	1,876	1,934	1,993	2,050	2,104	2,158	2,213	2,267
Shareholder's Equity	-52.8%	4,826	10,234	22,602	30,135	34,989	38,468	42,695	48,780	53,301	56,879	62,047	65,532	70,965	61,294	61,112	46,992	35,129	13,442	13,442	6,548	3,930
Retained Earnings	-1.4%	-415,325	-409,508	-396,932	-389,116	-384,207	-380,546	-376,157	-369,772	-364,921	-361,101	-355,255	-351,429	-345,553	-341,974	-338,575	-335,269	-331,917	-327,574	-326,918	-323,970	-321,941
Additional Paid-In Capital	0.1%	419,412	419,004	418,796	418,513	418,456	418,270	418,091	417,791	417,459	417,217	416,779	416,435	415,955	402,541	398,925	381,427	366,235	340,228	339,972	329,294	323,289
Shares Outstanding	1.6%	49,901	49,102	48,797	48,419	48,407	48,084	48,082	48,049	47,995	47,995	47,849	47,833	47,833	42,154	-	-	-	-	-	-	-
Float	-	-	-	-	31,829	-	-	-	36,254	-	-	-	101,114	-	-	-	83,968	-	-	-	10,128	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	50.7%	-4,815	-9,758	-5,671	-2,158	-3,680	-6,069	-4,968	-2,313	-2,758	-5,745	-3,457	-1,718	-3,045	-2,854	-2,989	-1,275	-3,250	-2,289	-2,544	-2,777	-1,457
Share Based Compensation	31.1%	80.00	61.00	50.00	50.00	82.00	162	275	275	242	248	314	480	526	440	250	150	196	204	223	251	175
Cashflow From Investing	26.2%	-158	-214	-336	-204	-78.00	3,363	250	7,721	-346	364	-366	-1,152	523	-182	-9,583	-3,082	3,683	-5,289	-232	472	-1,098
Cashflow From Financing	1824.5%	2,829	147	233	5.00	100	-	25.00	-	-	125	30.00	-4,761	12,794	3,041	17,160	10,675	25,687	-568	11,433	870	4,650

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AIM Income Statement

2024-03-31

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Clinical treatment programs – US	$ 40	$ 49
Total Revenues	40	49
Costs and Expenses:
Production costs	8
Research and development	1,951	2,052
General and administrative	3,815	2,292
Total Costs and Expenses	5,774	4,344
Operating loss	(5,734)	(4,295)
Gain (Loss) on investments	(92)	203
Interest and other income	81	199
Interest Expense and Other Finance Costs	(72)
(Loss) on sale of assets		(23)
Gain from sale of income tax operating losses		255
Net Loss	$ (5,817)	$ (3,661)
Basic loss per share	$ (0.12)	$ (0.08)
Diluted loss per share	$ (0.12)	$ (0.08)
Weighted average shares outstanding basic	49,458,023	48,399,950
Weighted average shares outstanding diluted	49,458,023	48,399,950

AIM Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 3,295,000	$ 5,439,000
Marketable investments	7,647,000	7,631,000
Funds receivable from New Jersey net operating loss and Other Receivables		1,184,000
Prepaid expenses and other current assets	364,000	302,000
Total current assets	11,306,000	14,556,000
Property and equipment, net	118,000	127,000
Right of use asset, net	763,000	697,000
Patent and trademark rights, net	2,314,000	2,313,000
Other assets	1,688,000	1,688,000
Total assets	16,189,000	19,381,000
Current liabilities:
Accounts payable	6,567,000	6,443,000
Accrued expenses	1,446,000	1,986,000
Current portion of operating lease liability	240,000	223,000
Current portion of note payable, net	1,623,000
Total current liabilities	9,876,000	8,652,000
Long-term liabilities:
Operating lease liability	537,000	495,000
Note payable, net	950,000
Total liabilities	11,363,000	9,147,000
Commitments and contingencies (Notes 9, 10 and 14)
Stockholders’ equity:
Common Stock, $0.001 par value, authorized shares - 350,000,000; issued and outstanding shares 50,251,933 and 49,102,484 as of March 31, 2024 and December 31, 2023, respectively	50,000	49,000
Additional paid-in capital	419,412,000	419,004,000
Accumulated deficit	(415,325,000)	(409,508,000)
Total stockholders’ equity	4,826,000	10,234,000
Total liabilities and stockholders’ equity	16,189,000	19,381,000
Series A Junior Participating Preferred Stock [Member]
Stockholders’ equity:
Preferred Stock, Value
Series B Convertible Preferred Stock [Member]
Stockholders’ equity:
Preferred Stock, Value	$ 689,000	$ 689,000

About AIM ImmunoTech Inc

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

CEO	Mr. Thomas K. Equels Esq., J.D., M.S.
WEBSITE	https://aimimmuno.com
INDUSTRY	Biotechnology
EMPLOYEES	22

AIM ImmunoTech Inc Frequently Asked Questions

What is the ticker symbol for AIM ImmunoTech Inc? What does AIM stand for in stocks?

AIM is the stock ticker symbol of AIM ImmunoTech Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AIM ImmunoTech Inc (AIM)?

As of Fri May 17 2024, market cap of AIM ImmunoTech Inc is 21.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AIM stock?

You can check AIM's fair value in chart for subscribers.

What is the fair value of AIM stock?

You can check AIM's fair value in chart for subscribers. The fair value of AIM ImmunoTech Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AIM ImmunoTech Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AIM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AIM ImmunoTech Inc a good stock to buy?

The fair value guage provides a quick view whether AIM is over valued or under valued. Whether AIM ImmunoTech Inc is cheap or expensive depends on the assumptions which impact AIM ImmunoTech Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AIM.

What is AIM ImmunoTech Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, AIM's PE ratio (Price to Earnings) is -0.68 and Price to Sales (PS) ratio is 108.94. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AIM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on AIM ImmunoTech Inc's stock?

In the past 10 years, AIM ImmunoTech Inc has provided -0.453 (multiply by 100 for percentage) rate of return.